Time in range centered diabetes care
Optimal glycemic control remains challenging and elusive for many people with diabetes. With the comprehensive clinical evidence on safety and efficiency in large populations, and with broader reimbursement, the adoption of continuous glucose monitoring (CGM) is rapidly increasing. Standardized visu...
Uložené v:
| Vydané v: | Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology Ročník 30; číslo 1; s. 1 |
|---|---|
| Hlavní autori: | , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Japan
01.01.2021
|
| Predmet: | |
| ISSN: | 0918-5739 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Optimal glycemic control remains challenging and elusive for many people with diabetes. With the comprehensive clinical evidence on safety and efficiency in large populations, and with broader reimbursement, the adoption of continuous glucose monitoring (CGM) is rapidly increasing. Standardized visual reporting and interpretation of CGM data and clear and understandable clinical targets will help professionals and individuals with diabetes use diabetes technology more efficiently, and finally improve long-term outcomes with less everyday disease burden. For the majority of people with type 1 or type 2 diabetes, time in range (between 70 and 180 mg/dL, or 3.9 and 10 mmol/L) target of more than 70% is recommended, with each incremental increase of 5% towards this target being clinically meaningful. At the same time, the goal is to minimize glycemic excursions: a recommended target for a time below range (< 70 mg/dL or < 3.9 mmol/L) is less than 4%, and time above range (> 180 mg/dL or 10 mmol/L) less than 25%, with less stringent goals for older individuals or those at increased risk. These targets should be individualized: the personal use of CGM with the standardized data presentation provides all necessary means to accurately tailor diabetes management to the needs of each individual with diabetes. |
|---|---|
| AbstractList | Optimal glycemic control remains challenging and elusive for many people with diabetes. With the comprehensive clinical evidence on safety and efficiency in large populations, and with broader reimbursement, the adoption of continuous glucose monitoring (CGM) is rapidly increasing. Standardized visual reporting and interpretation of CGM data and clear and understandable clinical targets will help professionals and individuals with diabetes use diabetes technology more efficiently, and finally improve long-term outcomes with less everyday disease burden. For the majority of people with type 1 or type 2 diabetes, time in range (between 70 and 180 mg/dL, or 3.9 and 10 mmol/L) target of more than 70% is recommended, with each incremental increase of 5% towards this target being clinically meaningful. At the same time, the goal is to minimize glycemic excursions: a recommended target for a time below range (< 70 mg/dL or < 3.9 mmol/L) is less than 4%, and time above range (> 180 mg/dL or 10 mmol/L) less than 25%, with less stringent goals for older individuals or those at increased risk. These targets should be individualized: the personal use of CGM with the standardized data presentation provides all necessary means to accurately tailor diabetes management to the needs of each individual with diabetes.Optimal glycemic control remains challenging and elusive for many people with diabetes. With the comprehensive clinical evidence on safety and efficiency in large populations, and with broader reimbursement, the adoption of continuous glucose monitoring (CGM) is rapidly increasing. Standardized visual reporting and interpretation of CGM data and clear and understandable clinical targets will help professionals and individuals with diabetes use diabetes technology more efficiently, and finally improve long-term outcomes with less everyday disease burden. For the majority of people with type 1 or type 2 diabetes, time in range (between 70 and 180 mg/dL, or 3.9 and 10 mmol/L) target of more than 70% is recommended, with each incremental increase of 5% towards this target being clinically meaningful. At the same time, the goal is to minimize glycemic excursions: a recommended target for a time below range (< 70 mg/dL or < 3.9 mmol/L) is less than 4%, and time above range (> 180 mg/dL or 10 mmol/L) less than 25%, with less stringent goals for older individuals or those at increased risk. These targets should be individualized: the personal use of CGM with the standardized data presentation provides all necessary means to accurately tailor diabetes management to the needs of each individual with diabetes. Optimal glycemic control remains challenging and elusive for many people with diabetes. With the comprehensive clinical evidence on safety and efficiency in large populations, and with broader reimbursement, the adoption of continuous glucose monitoring (CGM) is rapidly increasing. Standardized visual reporting and interpretation of CGM data and clear and understandable clinical targets will help professionals and individuals with diabetes use diabetes technology more efficiently, and finally improve long-term outcomes with less everyday disease burden. For the majority of people with type 1 or type 2 diabetes, time in range (between 70 and 180 mg/dL, or 3.9 and 10 mmol/L) target of more than 70% is recommended, with each incremental increase of 5% towards this target being clinically meaningful. At the same time, the goal is to minimize glycemic excursions: a recommended target for a time below range (< 70 mg/dL or < 3.9 mmol/L) is less than 4%, and time above range (> 180 mg/dL or 10 mmol/L) less than 25%, with less stringent goals for older individuals or those at increased risk. These targets should be individualized: the personal use of CGM with the standardized data presentation provides all necessary means to accurately tailor diabetes management to the needs of each individual with diabetes. |
| Author | Dovc, Klemen Battelino, Tadej |
| Author_xml | – sequence: 1 givenname: Klemen surname: Dovc fullname: Dovc, Klemen organization: Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia – sequence: 2 givenname: Tadej surname: Battelino fullname: Battelino, Tadej organization: Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33446946$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1j0tLxDAURrMYcR4K_gLpwoWbjmmSJrlLGXzBgJtxXfK4kUqb1qRd-O8tOK7Otzgc-LZkFYeIhNxUdF8xUA9uxD1f9opsKFS6rBWHNdnm_EUpAyrpJVlzLoQEITfk7tT2WLSxSCZ-YuEwTpjQF741FifMhTMJr8hFMF3G6zN35OP56XR4LY_vL2-Hx2PppFZTqX3FbRDKKO5EQBaYd8D0Qu65ldLUXhvwtQYLXlmHHmQIwLVSYQnUbEfu_7pjGr5nzFPTt9lh15mIw5wbJpSutWRcLurtWZ1tj74ZU9ub9NP8P2O_wpJNNw |
| CitedBy_id | crossref_primary_10_1186_s13098_025_01851_0 crossref_primary_10_1111_dme_15333 crossref_primary_10_1007_s13300_023_01468_4 crossref_primary_10_1007_s13300_022_01297_x crossref_primary_10_1186_s13098_023_01184_w crossref_primary_10_1111_crj_13613 crossref_primary_10_1186_s13690_024_01459_2 crossref_primary_10_1111_jdi_13618 crossref_primary_10_1016_j_diabres_2021_108917 crossref_primary_10_1111_dom_14576 crossref_primary_10_1016_j_clinthera_2025_05_002 crossref_primary_10_1016_S2213_8587_21_00245_X crossref_primary_10_1016_j_diabres_2022_109867 crossref_primary_10_1111_dme_15423 crossref_primary_10_1089_dia_2023_0112 crossref_primary_10_1007_s13340_023_00655_9 crossref_primary_10_2196_64585 crossref_primary_10_1111_dom_14527 crossref_primary_10_1111_dom_14906 crossref_primary_10_1056_NEJMcp2112175 crossref_primary_10_1038_s41746_022_00656_z crossref_primary_10_1089_dia_2021_2502 crossref_primary_10_1007_s12325_024_02943_5 crossref_primary_10_1007_s13300_022_01355_4 crossref_primary_10_1007_s12020_024_03683_w crossref_primary_10_1111_pedi_13391 crossref_primary_10_1016_j_numecd_2021_02_028 crossref_primary_10_1109_LSENS_2024_3436630 crossref_primary_10_1007_s13300_023_01427_z crossref_primary_10_1016_j_yjmcc_2025_06_013 crossref_primary_10_1007_s00112_021_01239_0 crossref_primary_10_3390_clinpract13020045 crossref_primary_10_3390_nu15194268 |
| ContentType | Journal Article |
| Copyright | 2021©The Japanese Society for Pediatric Endocrinology. |
| Copyright_xml | – notice: 2021©The Japanese Society for Pediatric Endocrinology. |
| DBID | NPM 7X8 |
| DOI | 10.1297/cpe.30.1 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 33446946 |
| Genre | Journal Article Review |
| GroupedDBID | --- 29B 2WC 53G 5GY 6J9 ABDBF ACUHS ADBBV ADRAZ AEGXH ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BKOMP CS3 DIK E3Z EBD EBS EJD ESX GX1 HYE JMI JSF JSH KQ8 M48 MOJWN M~E NPM OK1 PGMZT QF4 QN7 RJT RNS RPM RYR RZJ TKC TR2 TUS W2D XSB 7X8 OVT |
| ID | FETCH-LOGICAL-c687t-8d13bf47a73c4fe2f2dc9282f23d3b66a5d8a9d589b9d7bced96ff93877f68752 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 43 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000606646500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0918-5739 |
| IngestDate | Fri Jul 11 15:14:53 EDT 2025 Thu Jan 02 22:57:12 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 1 |
| Keywords | closed-loop glucose variability diabetes mellitus continuous glucose monitoring diabetes technology self-monitoring of blood glucose time in range |
| Language | English |
| License | 2021©The Japanese Society for Pediatric Endocrinology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c687t-8d13bf47a73c4fe2f2dc9282f23d3b66a5d8a9d589b9d7bced96ff93877f68752 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7783127 |
| PMID | 33446946 |
| PQID | 2478586236 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2478586236 pubmed_primary_33446946 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology |
| PublicationTitleAlternate | Clin Pediatr Endocrinol |
| PublicationYear | 2021 |
| SSID | ssj0029060 |
| Score | 2.3682203 |
| SecondaryResourceType | review_article |
| Snippet | Optimal glycemic control remains challenging and elusive for many people with diabetes. With the comprehensive clinical evidence on safety and efficiency in... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1 |
| Title | Time in range centered diabetes care |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33446946 https://www.proquest.com/docview/2478586236 |
| Volume | 30 |
| WOSCitedRecordID | wos000606646500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwED4BRYiF96O8FKSupm3s-DEhhKgYaNUBpG6Rc7alLmloC7-fc5rChITEEmVJ5FzO58_fne8D6BS2J5zCqBGGPSYyl7HCcmTc0mqEiORTtWrJixqN9GRixg3htmjKKtcxsQ7UboaRI--mQumM4DeX99U7i6pRMbvaSGhsQosTlIlerSbfWYTYybzmWExfs0xx0zSfTY3qYuXvON3_DizrBWaw_9-hHcBeAy2Th5UvHMKGL49gZ9gkz4-hE497JNMymccDBUksy4xCncmafk1iFdgJvA2eXh-fWSOSwFBqtWTa9XkRhLKKowg-DalDQ_uokHLHCylt5rQ1LtOmME4V6J2RIRiulQr0giw9ha1yVvpzSHpKSkJkhoKgFEjmE9ZZgegDgT4rdBtu19-fkxPGzIIt_exjkf9YoA1nKyPm1apbRs457TiNkBd_ePoSdtNYM1JTHFfQCjQF_TVs4-dyupjf1H-XrqPx8Avytq29 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Time+in+range+centered+diabetes+care&rft.jtitle=Clinical+pediatric+endocrinology+%3A+case+reports+and+clinical+investigations+%3A+official+journal+of+the+Japanese+Society+for+Pediatric+Endocrinology&rft.au=Dovc%2C+Klemen&rft.au=Battelino%2C+Tadej&rft.date=2021-01-01&rft.issn=0918-5739&rft.volume=30&rft.issue=1&rft.spage=1&rft_id=info:doi/10.1297%2Fcpe.30.1&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-5739&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-5739&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-5739&client=summon |